Reached full enrolment of Phase 1b study evaluating GT-02287 in Parkinson’s Disease (PD) with or without GBA1 mutations during 2Q 2025, earlier than anticipated Analysis of functional changes and biomarker activity at 90 days will be available during 4Q 2025 In July 2025 following the close of 2Q 2025, Gain completed an underwritten public offering that resulted in approximately $7.1 million of net proceeds BETHESDA, Md.,... Read More

BETHESDA, Md., July 24, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next-generation of allosteric small molecule therapies, today announced that the Company’s management team will participate in a fireside chat and one-on-one meetings at BTIG’s Annual Virtual Biotechnology Conference, being held... Read More

BETHESDA, Md., July 16, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced the pricing of an underwritten public offering of 4,501,640 shares of its common stock and warrants to purchase up to an aggregate of 2,250,820 shares of... Read More

BETHESDA, Md., July 15, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock (or common stock equivalents in lieu thereof) and warrants... Read More

As of June 30 th , 16 participants have enrolled in the Phase 1b, ahead of the original goal of at least 15 total participants by 3Q 2025 Analysis of 90-day biomarker activity from cerebrospinal fluid (CSF) in all participants currently enrolled is now expected to also track earlier; available in 4Q 2025 instead of 1Q 2026 Gain will continue screening patients for enrollment through July 31 st , 2025, at the request of... Read More

BETHESDA, Md., June 10, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President and CEO of Gain, will present at two upcoming investor conferences: H.C. Wainwright 6 th Annual Neuro Perspectives Hybrid... Read More

BETHESDA, Md., May 29, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced an oral presentation at the GBA1 Meeting 2025, being held June 5 th -7 th in Montreal, Canada. Details of the oral presentation are as follows : Date :... Read More

First Biomarker Analysis from Phase 1b Study of GT-02287 in Parkinson’s Disease Expected Mid-2025 BETHESDA, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the quarter ended March 31, 2025, and... Read More

GT-02287 protects dopaminergic neurons against mitochondrial toxin MPP+ suggesting an action on mitochondrial GCase in addition to its improvement of lysosomal GCase activity BETHESDA, Md., May 12, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule... Read More

BETHESDA, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President and CEO of Gain, will present and participate in one-on-one meetings at The Citizens Life Sciences Conference, being held May 7 th... Read More

BETHESDA, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. ( Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced an oral poster presentation at the International Association of Parkinsonism and Related Disorders (IAPRD) 30th World Congress on Parkinson's Disease and... Read More

GT-02287 oral presentation demonstrates new evidence of disease-modifying capacity in GBA1 and idiopathic Parkinson’s disease models Enrollment update provided for Phase 1b study Phase 1b study ongoing to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of GT-02287 in people with Parkinson’s disease; biomarker analysis to be conducted in Q2 2025 BETHESDA, Md., April 10, 2025 (GLOBE NEWSWIRE) -- Gain... Read More

BETHESDA, Md., March 28, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that a poster detailing the design of the Phase 1b clinical trial of GT-02287 in Parkinson’s disease will be presented at the AD/PD™ 2025 International... Read More

BETHESDA, Md., March 27, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the fourth quarter and year ended December 31, 2024, and provided a corporate update. “2024 was a year of significant progress for... Read More

BETHESDA, Md., March 14, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced the dosing of the first participant with Parkinson’s disease (PD) in its Phase 1b clinical trial of GT-02287, the Company’s lead allosteric small molecule... Read More

BETHESDA, Md., March 06, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Joanne Taylor, Ph.D., Senior Vice President of Research at Gain, will give an oral presentation on the Company’s clinical stage lead drug candidate... Read More

BETHESDA, Md., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today provided the following letter to shareholders from the Company’s President and CEO, Gene Mack: To our valued shareholders, With 2025 poised to be another pivotal year... Read More

BETHESDA, Md., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, Chief Executive Officer of Gain, will present at two upcoming investor conferences: BIO CEO & Investor Conference on Tuesday, February 11,... Read More

BETHESDA, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced the formation of its Clinical Advisory Board (CAB) to support the continued development of the Company’s lead drug candidate, GT-02287, in Parkinson’s... Read More

Gene Mack Has Served As CFO Since April 2024 And Interim CEO Since June 2024 Gianluca Fuggetta Will Assume The Role Of Senior Vice President, Finance BETHESDA, Md., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that... Read More

The Company has received approval to begin enrollment of the Phase 1b clinical trial in Australia Phase 1b clinical trial will assess safety and tolerability along with biomarkers during three months of dosing with GT-02287 in people diagnosed with Parkinson’s disease Phase 1b clinical trial follows successful Phase 1 study in which GT-02287 was safe and well tolerated while demonstrating GCase target engagement BETHESDA,... Read More

BETHESDA, Md., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, Chief Financial Officer and Interim Chief Executive Officer of Gain, will give a corporate presentation at Biotech Showcase 2025, being held... Read More

BETHESDA, Md., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reports financial results for the quarter ended September 30, 2024, and provides a corporate update. “The third quarter of 2024 marked substantial progress for Gain... Read More

GT-03842, Identified by the Company’s Magellan Drug Discovery Platform, Effectively Hinders Phosphorylation and Activation of DDR2 GT-03842 May Offer Potential Favourable Therapeutic Attributes for Oncology Compared to Traditional Kinase Inhibitors BETHESDA, Md., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery... Read More

BETHESDA, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that a poster detailing the use of the Company’s Magellan platform to discover novel allosteric discoidin domain receptor 2 (DDR2) inhibitors will be... Read More

BETHESDA, Md., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Jonas Hannestad, M.D., Ph.D., Chief Medical Officer of Gain, will give an oral presentation on the Company’s clinical stage lead drug candidate... Read More

GT-02287 Demonstrates Disease Modifying Capacity in Both GBA1 and Idiopathic Parkinson’s Disease Models GT-02287 Improves Mitochondrial Function and Provides Neuroprotective Effect in GBA1-Parkinson’s Disease Models GT-02287 Prevents Tau Accumulation in a Cellular Model BETHESDA, Md., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company... Read More

BETHESDA, Md., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, interim Chief Executive Officer and current Chief Financial Officer of Gain, will participate in two upcoming investor conferences: 3 rd... Read More

GT-02287 Increases Peripheral GCase Activity GT-02287 Demonstrates CNS Exposure Company to Host Webinar to Discuss Results at 8:30 AM ET Today BETHESDA, Md., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced the... Read More

Company To Discuss Positive Results Presented at the International MDS Congress and the Design of Phase 1b Trial in Parkinson’s Disease Patients Event Will Be Held on Monday, September 30, 2024, at 8:30 am ET BETHESDA, Md., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of... Read More

BETHESDA, Md., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced presentations, including two late-breakers, at Neuroscience 2024 featuring preclinical data supporting development of GT-02287, the Company’s clinical... Read More

BETHESDA, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, Interim CEO and current CFO of Gain, and Jonas Hannestad, M.D., Ph.D., Chief Medical Officer of Gain, will participate in a corporate... Read More

Results Include Safety, Tolerability, Pharmacokinetics, and Target Engagement GT-02287, in Development for GBA1 Parkinson’s Disease, on Track to Initiate Phase 1b Trial in Patients in Q4 2024 BETHESDA, Md., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small... Read More

Topline Results From MAD Phase 1 Study of GT-02287 on Track for August 2024 With Full Presentation at Upcoming Medical Conferences in Early Q4 2024 Initiation of Phase 1b Study of GT-02287 in Parkinson’s Disease Patients Anticipated in Q4 2024 BETHESDA, Md., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and... Read More

BETHESDA, Md. , Aug. 01, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that the Company’s interim-CEO and current CFO, Gene Mack, and Chief Medical Officer, Jonas Hannestad, will participate in a fireside chat and one-on-one... Read More

GT-02287 Well Tolerated With No Serious Adverse Events or Other Safety Signals Reported Additional Topline Data To Be Presented Mid-August GT-02287 on Track To Initiate Clinical Trial in Parkinson’s Disease Patients in Q4 2024 BETHESDA, Md., July 09, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the... Read More

BETHESDA, Md., June 28, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces that interim-CEO and current CFO Gene Mack will host a business and corporate update call on Monday, July 1, 2024, beginning 8:30am ET pre-market open.... Read More

Mr. Mack is the Company’s Current CFO Khalid Islam, PhD, Founder and Chairman of the Board, to serve as Executive Chairman BETHESDA, Md., June 27, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces that Matthias Alder has departed... Read More

BETHESDA, Md., June 27, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces the presentation of a poster at the Federation of European Neuroscience Societies (FENS) Forum 2024. The poster describes improvement in cognitive... Read More

BETHESDA, Md., June 25, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that the Company’s Chief Financial Officer, Gene Mack, will participate in a fireside chat and host virtual one-on-one meetings at H.C. Wainwright’s 5 th... Read More

BETHESDA, Md., June 13, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain” or the “Company”) (Nasdaq: GANX) today announced the pricing of an underwritten public offering of (i) 7,116,547 shares of its common stock at a public offering price of $1.35 per share and (ii) pre-funded warrants to purchase 1,031,602 shares of common stock in lieu of shares of common stock to certain investors. The pre-funded warrants will be... Read More

BETHESDA, Md., June 13, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain” or the “Company”) (Nasdaq: GANX) today announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock (or pre-funded warrants in lieu thereof) in an underwritten public offering. Gain expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock and... Read More

BETHESDA, Md., May 30, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that a late-breaking abstract with new data on GT-02287 has been accepted for presentation at FENS Forum 2024 being held June 25-29, 2024 in Vienna, Austria.... Read More

BETHESDA, Md., May 14, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reports financial results for the quarter ended March 31, 2024, and provides a corporate update. Corporate Highlights from Q1 2024 to Date Announced Positive Results... Read More

BETHESDA, Md., April 24, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, announces positive results from the single ascending dose (SAD) part of its Phase 1 study. GT-02287 was generally well tolerated up to and including the highest planned... Read More

BETHESDA, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces the appointment of Gene Mack, MBA as its chief financial officer, effective as of April 8, 2024. “We are thrilled to welcome Gene as our new CFO,”... Read More

BETHESDA, Md., April 01, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation allosteric small molecule therapies, today announces the appointment of Jonas Hannestad, M.D., Ph.D. as its chief medical officer, effective as of March 25, 2024. “I am pleased to welcome Jonas to Gain and look... Read More

BETHESDA, Md., March 26, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reports financial results for the year ended December 31, 2023 and provides a corporate update. Corporate Highlights from Q4 2023 to Date Presented data at AD/PD... Read More

BETHESDA, Md., March 15, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced participation in the upcoming Public Ventures Discovery Day on March 19, 2024 at Old Parkland in Dallas, TX. Public Ventures Discovery Day Date: Tuesday,... Read More

BETHESDA, Md., March 05, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces the presentation of a poster at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD™ 2024) that... Read More

BETHESDA, Md., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, announces the initiation of the Multiple Ascending Dose (MAD) part of the Phase 1 clinical trial of GT-02287, Gain’s lead drug candidate for the treatment of GBA1... Read More

BETHESDA, Md., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (Nasdaq: GANX), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced it is holding a 2024 Research & Development update on recent in vivo data for GT-02287 along with valuable insights from Key Opinion Leaders. Event Details “Beyond Symptomatic... Read More

BETHESDA, Md., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. , (Nasdaq: GANX), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, announces preclinical data demonstrating that its clinical-stage GCase regulator GT-02287 provided neuroprotection and restored motor function in Parkinson’s disease models following delayed... Read More

BETHESDA, Md., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. , (Nasdaq: GANX), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, announces preclinical data demonstrating that its clinical-stage GCase regulator GT-02287 provided neuroprotection and restored motor function in Parkinson’s disease models following delayed... Read More

BETHESDA, Md., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain,” or the “Company”), a biotechnology company leading the discovery and development of allosteric small molecule therapies, today releases the following letter to stockholders from its President and Chief Executive Officer Matthias Alder. Dear Fellow Stockholders, With the start of a new year, I want to take a moment to reflect on... Read More

BETHESDA, Md., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that a late-breaking abstract with new data of GT-02287 in preclinical models of Parkinson’s disease has been accepted for a platform presentation at the 20... Read More

BETHESDA, Md., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (the “Company”), a biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that the Company’s Chief Executive Officer, Matthias Alder, will participate in a fireside chat, hosted by FORCE Family Office, with John Vandermosten, CFA, Senior Analyst for Zacks... Read More

Compounds significantly restored β-Gal function and reduced intracellular toxic substrates in model of GM1 gangliosidosis Results published in PLOS ONE in collaboration with Institute for Research in Biomedicine BETHESDA, Md., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (Nasdaq: GANX), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small... Read More

BETHESDA, Md., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. , (Nasdaq: GANX), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Matthias Alder, Chief Executive Officer, will participate on a panel during the AI Driven Drug Discovery Summit taking place at the Sheraton Boston Hotel, in Boston,... Read More

BETHESDA, Md., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain” or the “Company”) (Nasdaq: GANX) today announced the closing of an underwritten public offering of 2,545,000 shares of its common stock and warrants to purchase up to an aggregate of 1,272,500 shares of its common stock at a combined public offering price of $2.005 per share and accompanying warrant, including 331,956 shares of common stock and... Read More

BETHESDA, Md., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain” or the “Company”) (Nasdaq: GANX) today announced the pricing of an underwritten public offering of 2,213,044 shares of its common stock and warrants to purchase up to an aggregate of 1,106,522 shares of its common stock at a combined public offering price of $2.005 per share and accompanying warrant. The public offering price for each set of two... Read More

BETHESDA, Md., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain” or the “Company”) (Nasdaq: GANX) today announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock and warrants to purchase common stock in an underwritten public offering. Gain expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock and/or... Read More

BETHESDA, Md., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced financial results for the third quarter ended September 30, 2023, and highlighted recent corporate progress. “With the compelling preclinical data we... Read More

BETHESDA, Md., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced dosing of the first two subjects in a Phase 1 clinical trial of GT-02287, Gain’s lead drug candidate for the treatment of GBA1 Parkinson’s disease. The... Read More

BETHESDA, Md., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (the “Company”), a biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that the Company’s Chief Executive Officer, Matthias Alder, will participate in a fireside chat and host one-on-one meetings at Cantor Fitzgerald Global Healthcare Conference taking... Read More

BETHESDA, Md., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. , (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Matthias Alder, Chief Executive Officer of Gain Therapeutics, will deliver a featured presentation at the Cambridge Healthtech Institute’s 2nd Annual... Read More

First drug candidate identified with Gain’s proprietary computational drug discovery platform SEE-Tx® to enter clinical development phase BETHESDA, Md., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that the Company has received... Read More

Treatment with GT-02287 also restored glucocerebrosidase (GCase) enzymatic function, reduced aggregated α-synuclein, neuroinflammation and neuronal death, increased dopamine levels and improved motor function Data presented at the International Congress of Parkinson's Disease and Movement Disorders ® Gain remains on track to begin a Phase 1 clinical study of GT-02287 later this year BETHESDA, Md., Aug. 28, 2023 (GLOBE... Read More

HREC application submitted; on track to initiate Phase 1 clinical study of GT-02287 this year Acceptance of late breaking abstract for presentation at the International Congress of Parkinson’s Disease and Movement Disorders ® in Copenhagen, Denmark BETHESDA, Md., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development... Read More

BETHESDA, Md., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. , (Nasdaq: GANX), a biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that a late breaking abstract highlighting the company’s lead program, GT-02287, has been accepted for presentation at the upcoming International Congress of Parkinson's Disease and Movement... Read More

BETHESDA, Md., July 31, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of allosteric small molecule therapies, today announced that members of management will participate in a fireside chat at the 2023 BTIG Virtual Biotechnology Conference on Tuesday, August 8 at 9:30 a.m. ET and host investor meetings. To listen to the... Read More

BETHESDA, Md., June 01, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of allosteric small molecule therapies, today announced that Matthias Alder, Chief Executive Officer, will present at the Jefferies Healthcare Conference, taking place June 7-9 in New York, NY. Jefferies Healthcare Conference Date: Wednesday, June 7,... Read More

Successfully completed GLP toxicology studies for lead program GT-02287 in GBA1 Parkinson’s disease Company is on track to submit application for start of Phase 1 clinical trial of GT-02287 to the Human Research Ethics Committee (HREC) in Australia in mid-2023 Received a $2.8 million (CHF $2.5 million) grant from Innosuisse, the Swiss Innovation Agency, to advance the development of GT-02287 in GBA1 Parkinson’s disease... Read More

BETHESDA, Md., May 03, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX), a biotechnology company leading the discovery and development of allosteric small molecule therapies, today announced that Innosuisse, the Swiss Innovation Agency, supports GT Gain Therapeutics SA with the amount of CHF 2.5 million (~$2.8 million) to develop GT-02287, Gain’s lead program for GBA1 Parkinson’s disease. The Company’s Swiss... Read More

BETHESDA, Md., April 12, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of allosteric small molecule therapies, today announced the appointment of C. Evan Ballantyne as the Company’s Chief Financial Officer, effective immediately. Mr. Ballantyne succeeds Salvatore Calabrese, who is expected to remain employed by the... Read More

BETHESDA, Md., March 29, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of allosteric small molecule therapies, today announced the presentation of new pre-clinical data supporting the potential of its structurally targeted allosteric regulators (STARs) of glucocerebrosidase (GCase) to prevent neurodegeneration in... Read More

Company expects completion of IND-enabling studies of GT-02287 in H1 2023 Submission of dossier to start Phase 1 clinical trial of GT-02287 in GBA1 Parkinson’s Disease expected by mid-year 2023 $22.1 million in cash and cash equivalents and marketable securities as of December 31, 2022 €1.2 million non-dilutive grant awarded to Company-led consortium to advance research program in Alpha-1 Antitrypsin Deficiency BETHESDA,... Read More

BETHESDA, Md., March 22, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational drug discovery platform identifying novel allosteric binding sites and creating small molecule therapies, today announced that it will participate in a virtual panel discussion on recent advances in AI-enabled computational... Read More

BETHESDA, Md., March 21, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced that Eurostars and Innosuisse have awarded a grant in the aggregate amount of €1.2 million to a consortium led by Gain Therapeutics... Read More

BETHESDA, Md., March 09, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced that Matthias Alder, Chief Executive Officer, will present at the Oppenheimer 33 rd Annual Healthcare... Read More

BETHESDA, Md., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, presented new pre-clinical data from its Gaucher disease program in a poster presentation at the 19 th Annual WORLD... Read More

BETHESDA, Md., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced that the Company will present new preclinical data at the following upcoming scientific and medical... Read More

BETHESDA, Md., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced that Matthias Alder, CEO, will present a corporate update at the Sidoti Small-Cap Virtual Investor... Read More

Accumulating Preclinical Data Provide Further Support for Disease-Modifying Potential of Brain Penetrant Investigational Small Molecule Therapeutic, GT-02287 Results Presented at the Shaare Zedek Medical Center GBA-Parkinson’s Disease Symposium Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational drug discovery platform... Read More

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced that Matthias Alder, the Company’s current Chief Operating Officer, has been appointed as the Company’s Chief Executive Officer, effective immediately. He... Read More

Treatment with GT-02287 Resulted in a Significant Dose-Dependent Improvement of Cellular Lysosomal Health and Fine Motor Skills Results Presented at the International Congress of Parkinson’s Disease and Movement Disorders 2022 Annual Meeting in Madrid, Spain Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational drug discovery... Read More

Presenting Preclinical Data at 2022 International Congress of Parkinson’s Disease and Movement Disorders in Madrid, Spain Upcoming Presentation on GBA-PD program at First International Symposium on GBA-PD in Jerusalem, Israel Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric... Read More

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced that the company’s Chief Operating Officer, Matthias Alder, will present and host one-on-one meetings at the H.C. Wainwright 24 th Annual Global Investment... Read More

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced its financial results for the second quarter ended June 30, 2022, and highlighted recent corporate progress. “We move into the second half of 2022 having... Read More

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced that members of management will participate in a fireside chat at the 2022 BTIG Biotechnology Conference on Tuesday, August 9 at 12 p.m. ET and host... Read More

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced that the company’s Chief Operating Officer, Matthias Alder, will present and host one-on-one meetings at the Jefferies Healthcare Conference taking place... Read More

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced that the company’s Chief Executive Officer, Eric Richman, will present and host one-on-one meetings at the H.C. Wainwright Global Investment Conference... Read More

Presented Supportive Preclinical Data for Lead Candidate GT-02287 at Recent Medical Meetings Further Validating Therapeutic Potential and Clinical Study in Parkinson’s Disease and Gaucher’s Disease. $34.34 Million in Cash as of March 31, 2022, Provides Runway into Second half of 2023 and a Strong Cash Position to Transition the Company’s Lead Program into Clinical Trials Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the... Read More

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today presented additional confirmatory data from its Gaucher disease program. The results were highlighted in an oral presentation at the 1 st IWGDD Symposium being held... Read More

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company applying its proprietary computational discovery platform to identify novel targets and small molecule treatments, today announced that it presented positive pre-clinical data from its GBA Parkinson’s Disease (PD) program. The results were highlighted in a poster presentation at the XXVII World Congress on Parkinson’s Disease and... Read More

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming the drug discovery paradigm with structurally targeted allosteric regulators identified with its proprietary computational discovery platform, today announced that Chief Executive Officer Eric Richman will participate in a fireside chat during the B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference, and... Read More

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company transforming the drug discovery paradigm with structurally targeted allosteric regulators identified with its proprietary computational discovery platform, today presented new pre-clinical data from its Parkinson’s Disease (PD) program. The results were highlighted in a poster presentation at the 2022 Synuclein Meeting being held April 12 - 15, 2022, in... Read More

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company transforming the drug discovery paradigm with structurally targeted allosteric regulators identified with its proprietary computational discovery platform, today presented new pre-clinical data from its Gaucher Disease (GD) program. The results were highlighted in a poster presentation at the 2022 Glycolipid and Sphingolipid Biology GRC being held March... Read More

$36.88 Million in cash as of December 31, 2021, provides runway into second half of 2023 and a strong cash position to transition the Company’s lead program into clinical trials Compelling preclinical data presented on lead program GBA1 Parkinson’s Disease at multiple scientific conferences supports transition to clinical stage company with FIH trial by year end Entered into multi-target deal with Zentalis Pharmaceuticals to... Read More

Study results provide additional validation that SEE-Tx platform identifies brain-penetrant small molecules ideally suited for CNS diseases caused by protein misfolding Demonstration of in vitro and in vivo functional efficacy in neurodegenerative disease with GCase causality First demonstration of an allosteric regulator with functional activity in both Parkinson’s and Alzheimer’s disease models Gain Therapeutics, Inc.... Read More

Oppenheimer 32 nd Annual Healthcare Conference AD/PD™ 2022 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders Krabbe Translational Research Network Meeting Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on identifying and optimizing allosteric binding sites that have never been targeted in neurodegenerative diseases and lysosomal storage... Read More

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company transforming the drug discovery paradigm with structurally targeted allosteric regulators (STARs) identified with its proprietary computational discovery platform, today presented new pre-clinical data from its Gaucher Disease (GD) program. These results were highlighted in a late breaking abstract presentation at the 18 th Annual WORLDSymposium on... Read More

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming and accelerating drug discovery with structurally targeted allosteric regulators identified with its proprietary computational discovery platform, today held its inaugural research and development day webinar. Capitalizing on significant advances in computational biology and drug discovery, the Company has applied its... Read More

Neuroscience and Beyond: Harnessing Computational Technology and Allosteric Modulators to Drug the Undruggable 18 th Annual WORLDSymposium AD/PD™ 2022 Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on identifying and optimizing allosteric binding sites that have never been targeted in neurodegenerative diseases and lysosomal storage disorders, today announced that it will be hosting an R&D... Read More

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on identifying and optimizing allosteric binding sites that have never been targeted in neurodegenerative diseases and lysosomal storage disorders, today announced that Chief Executive Officer Eric Richman, will participate in the H.C. Wainwright Bioconnect Conference and invites investors to participate via webcast. Please see additional... Read More

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding sites never before targeted in neurodegenerative diseases and lysosomal storage disorders, today announced the grant of an option to purchase 200,000 shares of the Gain’s common stock and of 200,000 restricted stock units of Gain’s common stock to Matthias Alder, its Chief... Read More

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding sites never before targeted in neurodegenerative diseases and lysosomal storage disorders, today announced a scientific update on the company’s Krabbe disease program. Gain is developing allosteric regulators to stabilize the galactosylceramidase (GALC) enzyme and reduce... Read More

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on identifying and optimizing allosteric binding sites that have never been targeted in neurodegenerative diseases and lysosomal storage disorders, today announced that Chief Executive Officer Eric Richman and Chief Scientific Officer Xavier Barril, Ph.D. of Gain Therapeutics, will present a corporate overview at the Imagine AI + Healthcare... Read More

Data from Patient-Derived iPSC Study Evaluating STAR Compounds Show Positive Effects on Disease Onset and Progression; Full Data Presented at MJFF’s Parkinson's Disease Therapeutics Conference Appoints Matthias Alder as Chief Operating Officer and Appoints 5 Members to Newly Formed Scientific Advisory Board $40.98 Million in Cash as of September 30, 2021, Provides Runway into Second half of 2023 and a Strong Cash Position to... Read More

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding sites never before targeted in neurodegenerative diseases and lysosomal storage disorders, today presented preclinical data during a poster session at the Society for Neuroscience Annual Meeting, being held virtually from November 8 – 11, 2021. The findings demonstrate that the... Read More

Study results demonstrate first small molecule approach to significantly reduce phosphorylated and aggregated -synuclein and increase GCase protein levels with transport to the lysosomes in iPSC dopaminergic neurons Results presented at Michael J. Fox Foundation’s Therapeutic Development Webinar Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company directly addressing the urgent need for... Read More

In-Person Dates: November 16 th -17 th Virtual Dates: November 18 th -19 th Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding sites never before targeted in neurodegenerative diseases and lysosomal storage disorders, today announced that Eric Richman, Chief Executive Officer of Gain Therapeutics, will present at the 12 th Annual... Read More

The Michael J. Fox Foundation’s Parkinson’s Disease Therapeutics Webinars Society of Neuroscience 50th Anniversary Meeting Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding sites never before targeted in neurodegenerative diseases and lysosomal storage disorders, today announced members of the Company’s management team will be... Read More

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “company”), a biotechnology company focused on identifying and optimizing allosteric binding sites never before targeted in neurodegenerative diseases and lysosomal storage disorders, today announced the formation of its Scientific Advisory Board (SAB). Luca Benatti, Ph.D. will serve as chair of the SAB. Additional appointments include Samuel Broder, M.D.; Lorenzo Leoni,... Read More

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding sites never before targeted in neurodegenerative diseases and lysosomal storage disorders, today announced the appointment of Matthias Alder as Chief Operating Officer to advance the Company’s strategic and operational objectives, including the establishment of additional... Read More

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding sites never before targeted in neurodegenerative diseases and lysosomal storage disorders, today announced that Eric Richman, Chief Executive Officer of Gain Therapeutics, will present at the Cantor Virtual Global Healthcare Conference and invites investors to participate via... Read More

Conference Dates: September 20 th -23 rd Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding sites never before targeted in neurodegenerative diseases and lysosomal storage disorders, today announced that Eric Richman, Chief Executive Officer of Gain Therapeutics, will present at the Oppenheimer Fall Healthcare Life Sciences &... Read More

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding sites never before targeted in neurodegenerative diseases and lysosomal storage disorders, today announced that Manolo Bellotto, Ph.D., General Manager and President at Gain, will present an overview on the Company’s proprietary Structurally Targeted Allosteric Regulators (STARs)... Read More

GT-02287and GT-02329 compounds display positive effects on GCase activity and related parameters Study results demonstrate an increase in GCase protein levels with transport to the lysosomes and decrease of glucosylceramide and α-synuclein-p129 levels Comprehensive study results to be presented at Michael J. Fox Foundation’s upcoming Innovating from Drug Discovery to the Clinic: Novel Approaches to PD Therapeutic Development... Read More

GT-02287and GT-02329 compounds display positive effects on GCase activity and related parameters Study results demonstrate an increase in GCase protein levels with transport to the lysosomes and decrease of glucosylceramide and α-synuclein-p129 levels Comprehensive study results to be presented at Michael J. Fox Foundation’s upcoming Innovating from Drug Discovery to the Clinic: Novel Approaches to PD Therapeutic Development... Read More

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding sites never before targeted in neurodegenerative diseases and lysosomal storage disorders, today announced that Eric Richman, Chief Executive Officer of Gain Therapeutics, will present at the H.C. Wainwright 23 rd Annual Global Investment Conference being held virtually from... Read More

Announced Multi-Target Drug Discovery Collaboration with Zentalis Pharmaceuticals in Oncology Granted Two Patents for Compounds that Stabilize G-Case for Gaucher's Disease and other Synucleinopathies including Parkinson's Disease, Lewy Body Dementia and Alzheimer’s Disease $43.2 Million in Cash as of June 30, 2021, Provides Runway into Second half of 2023 and a Strong Cash Position to Advance the Company’s Programs Gain... Read More

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and optimizing novel allosteric binding sites on proteins responsible for neurodegenerative diseases and lysosomal storage disorders, today announced that Eric Richman, Chief Executive Officer of Gain Therapeutics, will present a corporate overview at the BTIG Virtual Biotechnology Conference being... Read More

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric binding sites that have never before been targeted, today announced the publication of two PCT patents. PCT/IB2020/061158 and PCT/IB2020/0611156 are directed at compounds targeting misfolded beta-​glucocerebrosidase (GBA) and galactosylceramidase (GALC) respectively,... Read More

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric binding sites that have never before been targeted, today announced that Eric Richman, Chief Executive Officer of Gain Therapeutics, will present a corporate overview at the Jefferies Virtual Healthcare Conference being held on June 1 – 4. Jefferies Virtual Healthcare... Read More

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric binding sites that have never before been targeted, today announced that Eric Richman, Chief Executive Officer of Gain Therapeutics, will present a corporate overview at the 2021 RBC Capital Markets Global Healthcare Virtual Conference and at the Oppenheimer Rare & Orphan... Read More

Completed successful initial public offering and raised $46 million in gross proceeds Appointed four new independent board of directors to strengthen leadership team Signed a multi-target collaboration agreement with Zentalis Pharmaceuticals (Nasdaq: ZNTL) to discover new product candidates for the treatment of cancer Presented positive pre-clinical lysosomal storage target data at annual WorldSymposium™ Expect to complete... Read More

Compounds reverse the neurodegenerative process observed in a Parkinson’s disease in vivo model Compounds are novel allosteric regulators that bind, stabilize and restore activity of mutated GCase Compounds decrease both phosphorylated and aggregated α -synuclein levels in vitro and in vivo Gain Therapeutics, Inc. (NASDAQ: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by using... Read More

Gain Therapeutics, Inc. (NASDAQ: GANX) (“Gain”) a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric binding sites that have never before been targeted, today announced that Eric Richman, Chief Executive Officer of Gain Therapeutics, will present a corporate overview at the B. Riley Securities’ Virtual Neuroscience Conference being held on April 28 - 29. B. Riley Securities’... Read More

Gain Therapeutics, Inc. (NASDAQ: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric binding sites that have never before been targeted, today announced a poster presentation at the International Association of Parkinsonism and Related Disorders (IAPRD) 2021 World Congress being held virtually May 1-4, 2021. The presentation will highlight data demonstrating... Read More

Collaboration to use Gain’s proprietary Site-Directed Enzyme Enhancement Therapy (SEE-Tx™) computational platform technology to identify new and previously difficult-to-drug oncology targets Gain Therapeutics, Inc. (NASDAQ: GANX) (“Gain”) today announced a multi-target collaboration agreement with Zentalis Pharmaceuticals (NASDAQ: ZNTL) to discover new product candidates for the treatment of cancer. Gain will use its... Read More

Coya Therapeutics, Inc. , (Coya™), a clinical-stage biotechnology company developing first-in-class approaches utilizing autologous regulatory T cells (Tregs) and Treg-derived exosome therapeutics for neurodegenerative and autoimmune diseases, today announced that it has appointed Hideki Garren, M.D., Ph.D., Chief Medical Officer of Prothena and Dov Goldstein, M.D., Chief Financial Officer and Chief Business Officer of... Read More

Gain Therapeutics, Inc. (“Gain”) today announced the closing of its initial public offering of 3,636,364 shares of its common stock and full exercise of the underwriters’ overallotment option to purchase 545,454 additional shares of common stock, at a public offering price of $11.00 per share. The gross proceeds to Gain from the offering, before deducting underwriting discounts and commissions and other offering expenses... Read More